0001062993-24-006959.txt : 20240322
0001062993-24-006959.hdr.sgml : 20240322
20240322163238
ACCESSION NUMBER: 0001062993-24-006959
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240320
FILED AS OF DATE: 20240322
DATE AS OF CHANGE: 20240322
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith Ernest S.
CENTRAL INDEX KEY: 0001747769
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38624
FILM NUMBER: 24775753
MAIL ADDRESS:
STREET 1: 1895 MOUNT HOPE AVENUE
CITY: ROCHESTER
STATE: NY
ZIP: 14620
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VACCINEX, INC.
CENTRAL INDEX KEY: 0001205922
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 161603202
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1895 MOUNT HOPE AVE
CITY: ROCHESTER
STATE: NY
ZIP: 14620
BUSINESS PHONE: 585-271-2700
MAIL ADDRESS:
STREET 1: 1895 MOUNT HOPE AVE
CITY: ROCHESTER
STATE: NY
ZIP: 14620
FORMER COMPANY:
FORMER CONFORMED NAME: VACCINEX INC
DATE OF NAME CHANGE: 20021114
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2024-03-20
0001205922
VACCINEX, INC.
VCNX
0001747769
Smith Ernest S.
C/O VACCINEX, INC.
1895 MOUNT HOPE AVENUE
ROCHESTER
NY
14620
0
1
0
0
SVP, Research & CSO
0
Common Stock
39
D
Stock Option (Right to Buy)
1491.0
2025-12-22
Common Stock
193
193
D
Stock Option (Right to Buy)
1491.0
2025-12-23
Common Stock
24
24
D
Stock Option (Right to Buy)
819.0
2029-03-14
Common Stock
38
38
D
Stock Option (Right to Buy)
1274.7
2030-02-24
Common Stock
38
38
D
Stock Option (Right to Buy)
615.3
2031-04-02
Common Stock
47
47
D
Stock Option (Right to Buy)
270.9
2032-04-01
Common Stock
95
95
D
Stock Option (Right to Buy)
83.9
2033-03-30
Common Stock
190
190
D
Stock Option (Right to Buy)
8.32
2024-03-20
4
A
0
1341
0
A
2034-03-20
Common Stock
1341
1341
D
Exercisable in full as of the date of this report.
This option vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date, except as otherwise provided in the award notice.
This option vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date, except as otherwise provided in the award notice.
This option vests one-fourth on each of the first four anniversaries of the March 31, 2023 grant date, except as otherwise provided in the award notice.
This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 20, 2024 grant date.
All figures in this Form 4 reflect the Issuer's 1-for-15 reverse stock split effected on September 25, 2023 and 1-for-14 reverse stock split effected on February 19, 2024.
/s/ Maurice Zauderer, Attorney-in-Fact for Ernest S. Smith
2024-03-22